Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOICE2TRIAL
2023-504262-32-01Phase 3Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tissue-plasminogen activator in ischemic stroke and Large-Vessel Ischemic Stroke (LVO), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Proportion of patients with modified Rankin Scale 0 to 1 at 90 days. Started Oct 2023; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic strokeLarge-Vessel Ischemic Stroke (LVO)
Beyond the preview
Go deeper on 2023-504262-32-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504262-32-01.